Consensus RxSight, Inc.

Equities

RXST

US78349D1072

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
52.77 ^USD	+1.70%		+0.82%	+30.88%

Apr. 04	RxSight Launches New Light Adjustable Lens Product	MT
Apr. 04	RxSight, Inc. Announces Commercial Launch of its Newest Light Adjustable Lens??, the LAL+??, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting	CI

Evolution of the average Target Price on RxSight, Inc.

Price target over the last 5 years

History of analyst recommendation changes

af07d9a.RsHTzTBbs9pH4y06ObCI5yQUCzHOJ1jk2txT51flzOs.DaWJgx0C2_cul31XduDxok9jXFm4bTKHv-QRiTa3m4AXsbWaBGL1vgSPWg~bc0bfe1d957dfe1ddac8d8736b572acc

Analyst Recommendations on RxSight, Inc.

Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing	Apr. 02	MT
Needham Raises Price Target on RxSight to $64 From $53, Maintains Buy Rating	Feb. 29	MT
Oppenheimer Adjusts RxSight Price Target to $61 From $54, Maintains Outperform Rating	Feb. 29	MT
Stifel Adjusts Price Target on RxSight to $54 From $45, Maintains Buy Rating	Feb. 12	MT
Oppenheimer Raises RxSight Price Target to $54 From $50, Maintains Outperform Rating	Jan. 29	MT
Oppenheimer Raises RxSight Price Target to $50 From $46, Maintains Outperform Rating	Jan. 16	MT
Oppenheimer Ups Price Target on RxSight to $46 From $38, Maintains Outperform Rating	Jan. 08	MT
Needham Adjusts Price Target on RxSight to $41 From $35, Keeps Buy Rating	Jan. 08	MT
Wells Fargo Upgrades RxSight to Overweight From Equalweight, Price Target is $42	Dec. 13	MT
Stifel Starts RxSight With Buy Rating, $40 Price Target	Dec. 12	MT
Needham Adjusts RxSight Price Target to $30 From $36, Maintains Buy Rating	Nov. 10	MT
Oppenheimer Adjusts RxSight Price Target to $34 From $29, Maintains Outperform Rating	23-08-08	MT
Needham Adjusts Price Target on RxSight to $34 From $27, Maintains Buy Rating	23-07-12	MT
BTIG Adjusts Price Target on RxSight to $29 From $25, Maintains Buy Rating	23-06-05	MT
Wells Fargo Adjusts Price Target on RxSight to $27 From $17, Maintains Equalweight Rating	23-06-05	MT
Wells Fargo Adjusts RxSight Price Target to $17 From $15, Maintains Equal Weight Rating	23-05-10	MT
Oppenheimer Starts RxSight at Outperform With $23 Price Target, Sees Path to 'Meaningful' Gross Margin Expansion	23-04-13	MT
JPMorgan Adjusts Price Target on RxSight to $20 From $22, Maintains Overweight Rating	23-03-07	MT
Wells Fargo Downgrades RxSight to Equalweight From Overweight, Adjusts Price Target to $14 From $20	22-12-12	MT
Needham Raises RxSight's Price Target to $22 From $19, Maintains Buy Rating	22-08-09	MT
Needham Raises RxSight's Price Target to $19 From $18, Maintains Buy Rating	22-05-06	MT
Needham Starts RxSight at Buy With $18 Price Target	22-04-08	MT
RXSIGHT : BofA Securities Starts RxSight at Buy With $17 Price Target	21-08-24	MT
RXSIGHT : JPMorgan Initiates Coverage on RxSight With Overweight Rating, $16 Price Target	21-08-24	MT
RXSIGHT : BTIG Starts RxSight at Buy With $28 Price Target	21-08-24	MT